Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors.

about

Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors.

Item

http://www.wikidata.org/entity/Q55546375

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@en

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@nl

type

Item

label

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@en

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@nl

prefLabel

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@en

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@nl

P1476

Is there something wrong in pa ...... of novel BCR/ABL1 inhibitors.

@en

P2093

Peter Valent

http://www.w3.org/2001/XMLSchema#string

P2860

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.

The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

P304

e16-e17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2011.040873

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

3046288

http://www.w3.org/2001/XMLSchema#string